DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2014/0134726A1 D'amour Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2014/0134726A1 D'amour Et Al US 2014O134726A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0134726A1 D'Amour et al. (43) Pub. Date: May 15, 2014 (54) MARKERS OF DEFINITIVE ENDODERM (60) Provisional application No. 60/736,598, filed on Nov. 14, 2005, provisional application No. 60/532,004, (71) Applicant: ViaCyte, Inc., San Diego, CA (US) filed on Dec. 23, 2003, provisional application No. 60/586,566, filed on Jul. 9, 2004, provisional applica (72) Inventors: Kevin Allen D'Amour, San Diego, CA tion No. 60/587,942, filed on Jul 14, 2004. (US); Alan D. Agulnick, San Diego, CA (US); Emmanuel Edward Baetge, Encinitas, CA (US) Publication Classification (73) Assignee: ViaCyte, Inc., San Diego, CA (US) (51) Int. C. CI2N5/071 (2006.01) (21) Appl. No.: 14/066,441 (52) U.S. C. CPC .................................... CI2N5/0617 (2013.01) (22) Filed: Oct. 29, 2013 USPC ............................ 435/366; 435/325; 435/405 Related U.S. Application Data (57) ABSTRACT (63) Continuation of application No. 12/093.590, filed on Jul. 21, 2008, now Pat. No. 8,586,357, filed as appli Disclosed herein are reagent-cell complexes comprising one cation No. PCT/US06/43932 on Nov. 13, 2006, said or more definitive endoderm cells. Also described herein are application No. 12/093.590 is a continuation-in-part of compositions for detecting definitive endoderm. Method of application No. 11/021,618, filed on Dec. 23, 2004, enriching, isolating and/or purifying definitive endoderm now Pat. No. 7,510,876. cells are also disclosed. Patent Application Publication US 2014/0134726 A1 I"OIH Patent Application Publication May 15, 2014 Sheet 2 of 38 US 2014/0134726 A1 «…:%%;vez,sze?wº…«******&3&:;?&&#******************************…«,»º«º»,«», Patent Application Publication May 15, 2014 Sheet 3 of 38 US 2014/0134726 A1 ¿? re-was-----ee-earaxe-rrrrraaaaaa-swararaasaase-scal' ****************??--- ×, R saw xxxxx SS *re-assassessar Patent Application Publication May 15, 2014 Sheet 4 of 38 US 2014/0134726 A1 Patent Application Publication May 15, 2014 Sheet 5 of 38 US 2014/0134726 A1 Patent Application Publication May 15, 2014 Sheet 6 of 38 US 2014/0134726 A1 Patent Application Publication May 15, 2014 Sheet 7 of 38 US 2014/0134726 A1 A Sex & sess& &xpressies B $$$$$$xx 3&š8ws &&is sway awar. AX4 8 ----------~~ rurururururus warrarwa-awa is - 's Patent Application Publication May 15, 2014 Sheet 8 of 38 US 2014/0134726 A1 xx C2 s site Šs & e 38 8 & & S S. $8. & S. se 8 woxo s k S& & & &s 8 se see s & ass&six 888& Patent Application Publication May 15, 2014 Sheet 9 of 38 US 2014/0134726 A1 6."OIH Patent Application Publication May 15, 2014 Sheet 10 of 38 US 2014/0134726 A1 F.C.. O Patent Application Publication May 15, 2014 Sheet 12 of 38 US 2014/0134726 A1 Patent Application Publication May 15, 2014 Sheet 13 of 38 US 2014/0134726 A1 r^YYYYYYYYYYYYrrara-a-a-a-aa-ra----------------rra-a-a-a-a-a--------arrasaar aaaa-ra-warrara-na-na-marrawn---- **************************•••••••••••••••~~~~~~~~ SS - t 8 so R h h -…….……………………….……****************************~~~~~~~~~~ ---------------- ------------rrawawr Warrara-a-rammyxxxxxaaaaaaaaaaaaaaa------x-xxx-aawm-wears ??~~~~~*****••••••? tax. W Patent Application Publication May 15, 2014 Sheet 14 of 38 US 2014/0134726 A1 xis: &#3333ff332838433 & S. Ss & | FG. a. Patent Application Publication May 15, 2014 Sheet 15 of 38 US 2014/0134726 A1 Patent Application Publication May 15, 2014 Sheet 16 of 38 US 2014/0134726 A1 Patent Application Publication May 15, 2014 Sheet 17 of 38 US 2014/0134726 A1 Patent Application Publication May 15, 2014 Sheet 18 of 38 US 2014/0134726 A1 XXXXXXX-XXXXXa) ×××××× exxxsas WIWIWITITZ277||M|MIT saaaaassaxxxx.cccssoccasses US 2014/0134726 A1 ********************************************** C5wns s Patent Application Publication May 15, 2014 Sheet 20 of 38 US 2014/0134726 A1 s 00‘OIH *****************--~~~~ ******************************????????????????åååå,-,-,-,-,-,-,-,-,-,-,-,- $8 ******************…*..*,,+.*? sy X&$88s busiege anaeia ); ***************************>)*)*)*)*)*)*)*)*)*)*)(---,-,-,-,-).********************????????????? ****************************************************************************************************************************)*)*)*)*)*)*)*)*+,·,· Patent Application Publication May 15, 2014 Sheet 21 of 38 US 2014/0134726 A1 ?gyv? IZ(OIH ******************************~~~~~~~~~~~~~~~~~~~~~~~~~~~.~~~~~~~~~~); 888 S$8,8x8 8888: 8888.8 Strixww.sssssssssswsrxxx-xx-www.xxxxxwww.xw.xxxxxxwww.yesws.xxxxx xxxxxYxxxxxx Patent Application Publication May 15, 2014 Sheet 22 of 38 US 2014/0134726 A1 a-Yaaaaaaaaaaaa. aaaaaaaaaa-Maxxxaasaaraaaaaaaanx ************•~~~ "OIHZZ ----·- 888 8 X838 & 8 & 888. ^^^^^^^***********************~~~~~,~~~~~~~-------------~--~~~~~……………………………?? aNasswaaaaX-rw-W-----a-e'-a'--------a- x''Asakara'a-a-a-a-a-a-a- Patent Application Publication May 15, 2014 Sheet 23 of 38 US 2014/0134726 A1 : | c. s - $8 sawaxaaw: or soa &- & & uoissoluxetosses sixa vagelo8 seas Patent Application Publication May 15, 2014 Sheet 24 of 38 US 2014/0134726 A1 **************~~~~~~~~~,~~************** •?????• ~~~~~~~~~~~ s -------as-as-xx-aaraaaaaaaa-...-a, ------------------ Yaaaa-MaxM 88 SS & 8 . & 8 is R arra-aaaaaaaaaaaaaaaaaaSSaraaaaaaaaaaaaaaaaaaaaa (B) SS$8 V R towns Patent Application Publication May 15, 2014 Sheet 25 of 38 US 2014/0134726 A1 Patent Application Publication May 15, 2014 Sheet 26 of 38 US 2014/0134726 A1 w axe-rawa-N-awam asaasaxx-xx-aaaaaaaaaaaaa-Wa-Wentwaaaaaa~~~~~--~~~~); Patent Application Publication May 15, 2014 Sheet 27 of 38 US 2014/0134726 A1 ~~~~*~~~~#~~~~*~*~~~~.~~~~.~~~~…………; & servaxas-Naaaaaaasax ????? za~~===~~~~~~~~a~~ (~~~*~*****************************¿¿. #******************-------- ******************************)*)*)*)*)*)*)*)*)*)*)*)*)*)(---) (C Patent Application Publication May 15, 2014 Sheet 28 of 38 US 2014/0134726 A1 ***^^*^^******************************«*^^º««««…--~~~~!!!!!!………………………….… ----------TZ·! Patent Application Publication May 15, 2014 Sheet 29 of 38 US 2014/0134726 A1 SOXY SOX air Patent Application Publication May 15, 2014 Sheet 30 of 38 US 2014/0134726 A1 x s Srxys's waxyw$Yisrs-s-s s 8 S.wr s s 8. six it. gax SS s ***********gxºxºzºg: Patent Application Publication May 15, 2014 Sheet 31 of 38 US 2014/0134726A1 (B) ---------------M.-------------------as---------------------------asaaaa •••••¿•)›***********************·:- abamaxx-xxx AxAXXXX-AM-xxxxxxxxxaaaaaaaaassrs. $$$$$. | {4{ {| |{ •}} *}~~~~#~~~~#~~~~*~~~~#~?---- w ################## *~~~~~~~*~~~~*~~~~~~ axaaaaaaaaaaay's Patent Application Publication May 15, 2014 Sheet 32 of 38 US 2014/0134726A1 m is FIG. 32 Patent Application Publication May 15, 2014 Sheet 33 of 38 US 2014/0134726A1 (A) strachyury *~~~~'+'~~~~~~~~~~~~~~~~~);-)))-, Www.a.s. (C) Patent Application Publication May 15, 2014 Sheet 34 of 38 US 2014/0134726 A1 S&S $8:$rsssssssswasaraxxar S8-------'''''''''''''',: "... star------------ 3-SSSS&S -s areassessoaxxxYYYYYa-------axx-xx-s F.C. 3. Patent Application Publication May 15, 2014 Sheet 35 of 38 US 2014/0134726 A1 Siksis'' SS: wartw8taxxxxww. : ~~~#~~~~ 888: ------------------------------- º? FIG. 34 Patent Application Publication May 15, 2014 Sheet 36 of 38 US 2014/0134726 A1 8x8x #*! |{| {? * & Sarasara-earease-area SS S rwarxWraxxx-xxxxYxxws 8 & ico S &S %(*? ******************reeee!~~~~~~••••••••••••••••••••• FIG. Patent Application Publication May 15, 2014 Sheet 37 of 38 US 2014/0134726 A1 Patent Application Publication May 15, 2014 Sheet 38 of 38 US 2014/0134726 A1 x - $3. sexistern SSSSS------ (~~~. 8:S$ $&S --> *****j,w US 2014/0134726 A1 May 15, 2014 MARKERS OF DEFINITIVE ENDODERM the mature organism in addition to extraembryonic tissues (e.g. placenta) and germ cells. Although pluripotency imparts RELATED APPLICATIONS extraordinary utility upon hESCs, this property also poses 0001. This application is a nonprovisional application unique challenges for the study and manipulation of these which claims priority under 35 U.S.C. S 119(e) to U.S. Pro cells and their derivatives. Owing to the large variety of cell visional Patent Application No. 60/736,598, entitled MARK types that may arise in differentiating hESC cultures, the vast ERS OF DEFINITIVE ENDODERM, filed Nov. 14, 2005; majority of cell types are produced at very low efficiencies. this application is also a continuation-in-part of U.S. patent Additionally, success in evaluating production of any given application Ser. No. 1 1/021,618, entitled DEFINITIVE cell type depends critically on defining appropriate markers. ENDODERM, filed Dec. 23, 2004, which claims priority Achieving efficient, directed differentiation is of great impor under 35 U.S.C. S 119(e) as a nonprovisional application to tance for therapeutic application of hESCs. U.S. Provisional Patent Application No. 60/587,942, entitled 0006. In order to use hESCs as a starting material togen CHEMOKINE CELL SURFACE RECEPTOR FOR THE erate cells that are useful in cell therapy applications, it would ISOLATION OF DEFINITIVE ENDODERM, filed Jul 14, be advantageous to overcome the foregoing problems. For 2004; and U.S. Provisional Patent Application No. 60/586, example, it would be useful to identify and isolate cell types, 566, entitled CHEMOKINE CELL SURFACE RECEPTOR such as definitive endoderm, that can later differentiate into FOR THE ISOLATION OF DEFINITIVE ENDODERM, pancreatic islet/B-cells, as well as other useful cell types. filed Jul. 9, 2004. and U.S. Provisional Patent Application No. 60/532,004, entitled DEFINITIVE ENDODERM,
Load more

Recommended publications
  • The Landscape of Genomic Imprinting Across Diverse Adult Human Tissues
    Downloaded from genome.cshlp.org on October 3, 2021 - Published by Cold Spring Harbor Laboratory Press Research The landscape of genomic imprinting across diverse adult human tissues Yael Baran,1 Meena Subramaniam,2 Anne Biton,2 Taru Tukiainen,3,4 Emily K. Tsang,5,6 Manuel A. Rivas,7 Matti Pirinen,8 Maria Gutierrez-Arcelus,9 Kevin S. Smith,5,10 Kim R. Kukurba,5,10 Rui Zhang,10 Celeste Eng,2 Dara G. Torgerson,2 Cydney Urbanek,11 the GTEx Consortium, Jin Billy Li,10 Jose R. Rodriguez-Santana,12 Esteban G. Burchard,2,13 Max A. Seibold,11,14,15 Daniel G. MacArthur,3,4,16 Stephen B. Montgomery,5,10 Noah A. Zaitlen,2,19 and Tuuli Lappalainen17,18,19 1The Blavatnik School of Computer Science, Tel-Aviv University, Tel Aviv 69978, Israel; 2Department of Medicine, University of California San Francisco, San Francisco, California 94158, USA; 3Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA; 4Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, Massachusetts 02142, USA; 5Department of Pathology, Stanford University, Stanford, California 94305, USA; 6Biomedical Informatics Program, Stanford University, Stanford, California 94305, USA; 7Wellcome Trust Center for Human Genetics, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, OX3 7BN, United Kingdom; 8Institute for Molecular Medicine Finland, University of Helsinki, 00014 Helsinki, Finland; 9Department of Genetic Medicine and Development, University of Geneva, 1211 Geneva, Switzerland;
    [Show full text]
  • The Lavender Plumage Colour in Japanese Quail Is
    Bed’hom et al. BMC Genomics 2012, 13:442 http://www.biomedcentral.com/1471-2164/13/442 RESEARCH ARTICLE Open Access The lavender plumage colour in Japanese quail is associated with a complex mutation in the region of MLPH that is related to differences in growth, feed consumption and body temperature Bertrand Bed’hom1, Mohsen Vaez2,5, Jean-Luc Coville1, David Gourichon3, Olivier Chastel4, Sarah Follett2, Terry Burke2 and Francis Minvielle1,6* Abstract Background: The lavender phenotype in quail is a dilution of both eumelanin and phaeomelanin in feathers that produces a blue-grey colour on a wild-type feather pattern background. It has been previously demonstrated by intergeneric hybridization that the lavender mutation in quail is homologous to the same phenotype in chicken, which is caused by a single base-pair change in exon 1 of MLPH. Results: In this study, we have shown that a mutation of MLPH is also associated with feather colour dilution in quail, but that the mutational event is extremely different. In this species, the lavender phenotype is associated with a non-lethal complex mutation involving three consecutive overlapping chromosomal changes (two inversions and one deletion) that have consequences on the genomic organization of four genes (MLPH and the neighbouring PRLH, RAB17 and LRRFIP1). The deletion of PRLH has no effect on the level of circulating prolactin. Lavender birds have lighter body weight, lower body temperature and increased feed consumption and residual feed intake than wild-type plumage quail, indicating that this complex mutation is affecting the metabolism and the regulation of homeothermy. Conclusions: An extensive overlapping chromosome rearrangement was associated with a non-pathological Mendelian trait and minor, non deleterious effects in the lavender Japanese quail which is a natural knockout for PRLH.
    [Show full text]
  • Análise Integrativa De Perfis Transcricionais De Pacientes Com
    UNIVERSIDADE DE SÃO PAULO FACULDADE DE MEDICINA DE RIBEIRÃO PRETO PROGRAMA DE PÓS-GRADUAÇÃO EM GENÉTICA ADRIANE FEIJÓ EVANGELISTA Análise integrativa de perfis transcricionais de pacientes com diabetes mellitus tipo 1, tipo 2 e gestacional, comparando-os com manifestações demográficas, clínicas, laboratoriais, fisiopatológicas e terapêuticas Ribeirão Preto – 2012 ADRIANE FEIJÓ EVANGELISTA Análise integrativa de perfis transcricionais de pacientes com diabetes mellitus tipo 1, tipo 2 e gestacional, comparando-os com manifestações demográficas, clínicas, laboratoriais, fisiopatológicas e terapêuticas Tese apresentada à Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo para obtenção do título de Doutor em Ciências. Área de Concentração: Genética Orientador: Prof. Dr. Eduardo Antonio Donadi Co-orientador: Prof. Dr. Geraldo A. S. Passos Ribeirão Preto – 2012 AUTORIZO A REPRODUÇÃO E DIVULGAÇÃO TOTAL OU PARCIAL DESTE TRABALHO, POR QUALQUER MEIO CONVENCIONAL OU ELETRÔNICO, PARA FINS DE ESTUDO E PESQUISA, DESDE QUE CITADA A FONTE. FICHA CATALOGRÁFICA Evangelista, Adriane Feijó Análise integrativa de perfis transcricionais de pacientes com diabetes mellitus tipo 1, tipo 2 e gestacional, comparando-os com manifestações demográficas, clínicas, laboratoriais, fisiopatológicas e terapêuticas. Ribeirão Preto, 2012 192p. Tese de Doutorado apresentada à Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo. Área de Concentração: Genética. Orientador: Donadi, Eduardo Antonio Co-orientador: Passos, Geraldo A. 1. Expressão gênica – microarrays 2. Análise bioinformática por module maps 3. Diabetes mellitus tipo 1 4. Diabetes mellitus tipo 2 5. Diabetes mellitus gestacional FOLHA DE APROVAÇÃO ADRIANE FEIJÓ EVANGELISTA Análise integrativa de perfis transcricionais de pacientes com diabetes mellitus tipo 1, tipo 2 e gestacional, comparando-os com manifestações demográficas, clínicas, laboratoriais, fisiopatológicas e terapêuticas.
    [Show full text]
  • Communication in Asthmatic Airways Inflammation and Intercellular Gene
    Gene Expression Patterns of Th2 Inflammation and Intercellular Communication in Asthmatic Airways This information is current as David F. Choy, Barmak Modrek, Alexander R. Abbas, Sarah of September 28, 2021. Kummerfeld, Hilary F. Clark, Lawren C. Wu, Grazyna Fedorowicz, Zora Modrusan, John V. Fahy, Prescott G. Woodruff and Joseph R. Arron J Immunol 2011; 186:1861-1869; Prepublished online 27 December 2010; Downloaded from doi: 10.4049/jimmunol.1002568 http://www.jimmunol.org/content/186/3/1861 Supplementary http://www.jimmunol.org/content/suppl/2010/12/27/jimmunol.100256 http://www.jimmunol.org/ Material 8.DC1 References This article cites 63 articles, 10 of which you can access for free at: http://www.jimmunol.org/content/186/3/1861.full#ref-list-1 Why The JI? Submit online. by guest on September 28, 2021 • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2011 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Gene Expression Patterns of Th2 Inflammation and Intercellular Communication in Asthmatic Airways David F.
    [Show full text]
  • Chip-Seq Analysis to Explore DNA Replication Profile in Trifluridine
    ANTICANCER RESEARCH 39 : 3565-3570 (2019) doi:10.21873/anticanres.13502 ChIP-seq Analysis to Explore DNA Replication Profile in Trifluridine-treated Human Colorectal Cancer Cells In Vitro TAKASHI KOBUNAI 1* , KAZUAKI MATSUOKA 2* and TEIJI TAKECHI 1 1Taiho Pharmaceutical Co., Ltd., Translational Research Laboratory, Tokyo, Japan; 2Taiho Pharmaceutical Co., Ltd., Translational Research Laboratory (Tokushima office), Tokushima, Japan Abstract. Background/Aim: Trifluridine (FTD) is a key efficacy and a tolerable safety profile for previously treated component of the novel oral antitumor drug trifluridine/ metastatic colorectal cancer (2). tipiracil that has been approved for the treatment of metastatic In basic research, FTD, the active antitumor component of colorectal cancer. In this study, a comprehensive analysis of FTD/TPI, is an antineoplastic thymidine analog (3), efficiently DNA replication profile in FTD-treated colon cancer cells was incorporated into genomic DNA in tumor cells (4-7). FTD performed. Materials and Methods: HCT-116 cells were transported into the cytoplasm of tumor cells by equilibrative exposed to BrdU or FTD and subjected to DNA immuno- nucleoside transporter 1 and 2 is phosphorylated to mono- precipitation. Immunoprecipitated DNA was sequenced; the phosphate, diphosphate, and triphosphate (FTD-TP) forms by density of aligned reads along the genome was calculated. Peak thymidine kinase 1 and nucleoside diphosphate kinase, finding, gene ontology, and motif analysis were performed using respectively. DNA polymerase α incorporates FTD-TP into MACS, GREAT, and MEME, respectively. Results: We identified DNA at sites aligned with adenine on the opposite strand (8). 6,043 and 5,080 high-confidence FTD and BrdU peaks in HCT- FTD/TPI exerts its antitumor activity in vivo predominantly 116 cells, respectively.
    [Show full text]
  • Downloaded with Ma- Disease D D
    bioRxiv preprint doi: https://doi.org/10.1101/483065; this version posted November 29, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. F1000Research 2016 - DRAFT ARTICLE (PRE-SUBMISSION) Bioinformatics Approach to Identify Diseasome and Co- morbidities Effect of Mitochondrial Dysfunctions on the Progression of Neurological Disorders Md. Shahriare Satu1, Koushik Chandra Howlader2, Tajim Md. Niamat Ullah Akhund3, Fazlul Huq4, Julian M.W. Quinn5, and Mohammad Ali Moni4,5 1Dept. of CSE, Gono Bishwabidyalay, Dhaka, Bangladesh 2Dept. of CSTE, Noakhali Science and Technology University, Noakhali, Bangladesh 3Institute of Information Technology, Jahangirnagar University, Dhaka, Bangladesh 4School of Biomedical Science, Faculty of Medicine and Health, The University of Sydney, Australia 5Bone Biology Division, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia Abstract Mitochondrial dysfunction can cause various neurological diseases. We therefore developed a quantitative framework to explore how mitochondrial dysfunction may influence the progression of Alzheimer’s, Parkinson’s, Hunting- ton’s and Lou Gehrig’s diseases and cerebral palsy through analysis of genes showing altered expression in these conditions. We sought insights about the gene profiles of mitochondrial and associated neurological diseases by investigating gene-disease networks, KEGG pathways, gene ontologies and protein-protein interaction network. Gene disease networks were constructed to connect shared genes which are commonly found between the neurological diseases and Mito- chondrial Dysfunction. We also generated KEGG pathways and gene ontologies to explore functional enrichment among them, and protein-protein interaction networks to identify the shared protein groups of these diseases.
    [Show full text]
  • Chromosome 20 Shows Linkage with DSM-IV Nicotine Dependence in Finnish Adult Smokers
    Nicotine & Tobacco Research, Volume 14, Number 2 (February 2012) 153–160 Original Investigation Chromosome 20 Shows Linkage With DSM-IV Nicotine Dependence in Finnish Adult Smokers Kaisu Keskitalo-Vuokko, Ph.D.,1 Jenni Hällfors, M.Sc.,1,2 Ulla Broms, Ph.D.,1,3 Michele L. Pergadia, Ph.D.,4 Scott F. Saccone, Ph.D.,4 Anu Loukola, Ph.D.,1,3 Pamela A. F. Madden, Ph.D.,4 & Jaakko Kaprio, M.D., Ph.D.1,2,3 1 Hjelt Institute, Department of Public Health, University of Helsinki, Helsinki, Finland 2 Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland 3 National Institute for Health and Welfare (THL), Helsinki, Finland 4 Department of Psychiatry, Washington University School of Medicine, St. Louis, MO Corresponding Author: Jaakko Kaprio, M.D., Ph.D., Department of Public Health, University of Helsinki, PO Box 41 (Manner- heimintie 172), Helsinki 00014, Finland. Telephone: +358-9-191-27595; Fax: +358-9-19127570; E-mail: [email protected] Received February 5, 2011; accepted June 21, 2011 2009). Despite several gene-mapping studies, the genes underlying Abstract liability to nicotine dependence (ND) remain largely unknown. Introduction: Chromosome 20 has previously been associated Recently, Han, Gelernter, Luo, and Yang (2010) performed a with nicotine dependence (ND) and smoking cessation. Our meta-analysis of 15 genome-wide linkage scans of smoking aim was to replicate and extend these findings. behavior. Linkage signals were observed on chromosomal regions 17q24.3–q25.3, 5q33.1–q35.2, 20q13.12–32, and 22q12.3–13.32. Methods: First, a total of 759 subjects belonging to 206 Finnish The relevance of the chromosome 20 finding is highlighted families were genotyped with 18 microsatellite markers residing by the fact that CHRNA4 encoding the nicotinic acetylcholine on chromosome 20, in order to replicate previous linkage findings.
    [Show full text]
  • TNF Expression Noncoding Rnas and LRRFIP1 Regulate
    Noncoding RNAs and LRRFIP1 Regulate TNF Expression Lihua Shi, Li Song, Michael Fitzgerald, Kelly Maurer, Asen Bagashev and Kathleen E. Sullivan This information is current as of September 26, 2021. J Immunol published online 24 February 2014 http://www.jimmunol.org/content/early/2014/02/21/jimmun ol.1302063 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2014/02/21/jimmunol.130206 Material 3.DCSupplemental Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on September 26, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2014 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published February 24, 2014, doi:10.4049/jimmunol.1302063 The Journal of Immunology Noncoding RNAs and LRRFIP1 Regulate TNF Expression Lihua Shi, Li Song, Michael Fitzgerald, Kelly Maurer, Asen Bagashev,1 and Kathleen E. Sullivan Noncoding RNAs have been implicated in the regulation of expression of numerous genes; however, the mechanism is not fully understood. We identified bidirectional, long noncoding RNAs upstream of the TNF gene using five different methods.
    [Show full text]
  • Rapalog-Mediated Repression of Tribbles
    Published OnlineFirst April 3, 2020; DOI: 10.1158/0008-5472.CAN-19-2366 CANCER RESEARCH | MOLECULAR CELL BIOLOGY Rapalog-Mediated Repression of Tribbles Pseudokinase 3 Regulates Pre-mRNA Splicing Bojana Stefanovska1,2,3, Cecile Edith Vicier1,2,3, Thibault Dayris2,4, Vasily Ogryzko5,†, Veronique Scott1,2,3, Ibrahim Bouakka1,2,3, Suzette Delaloge6, Anna Rocca1,2,3, Olivia Le Saux7, Olivier Tredan 7, Thomas Bachelot7, Fabrice Andre1,2,6, and Olivia Fromigue1,2,3 ABSTRACT ◥ Rapalogs have become standard-of-care in patients with induced deregulation of RNA splicing. Conversely, overexpres- metastatic breast, kidney, and neuroendocrine cancers. Never- sion of TRIB3 in a panel of cancer cell lines abolished theless, tumor escape occurs after several months in most the cytotoxic effects of rapalogs. These findings identify TRIB3 patients, highlighting the need to understand mechanisms of as a key component of the spliceosome, whose repression resistance. Using a panel of cancer cell lines, we show that contributes significantly to the mechanism of resistance to rapalogs downregulate the putative protein kinase TRIB3 (trib- rapalog therapy. bles pseudokinase 3). Blood samples of a small cohort of patients with cancer treated with rapalogs confirmed down- Significance: Independent of mTOR signaling, rapalogs induce regulation of TRIB3. Downregulation of TRIB3 was mediated cytoxicity by dysregulating spliceosome function via repression of by LRRFIP1 independently of mTOR and disrupted its inter- TRIB3, the loss of which may, in the long term, contribute to action with the spliceosome, where it participated in rapalog- therapeutic resistance. Introduction development of some derivatives overcame issues related to poor solubility and pharmacokinetics of the original rapamycin molecule.
    [Show full text]
  • "The Genecards Suite: from Gene Data Mining to Disease Genome Sequence Analyses". In: Current Protocols in Bioinformat
    The GeneCards Suite: From Gene Data UNIT 1.30 Mining to Disease Genome Sequence Analyses Gil Stelzer,1,5 Naomi Rosen,1,5 Inbar Plaschkes,1,2 Shahar Zimmerman,1 Michal Twik,1 Simon Fishilevich,1 Tsippi Iny Stein,1 Ron Nudel,1 Iris Lieder,2 Yaron Mazor,2 Sergey Kaplan,2 Dvir Dahary,2,4 David Warshawsky,3 Yaron Guan-Golan,3 Asher Kohn,3 Noa Rappaport,1 Marilyn Safran,1 and Doron Lancet1,6 1Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel 2LifeMap Sciences Ltd., Tel Aviv, Israel 3LifeMap Sciences Inc., Marshfield, Massachusetts 4Toldot Genetics Ltd., Hod Hasharon, Israel 5These authors contributed equally to the paper 6Corresponding author GeneCards, the human gene compendium, enables researchers to effectively navigate and inter-relate the wide universe of human genes, diseases, variants, proteins, cells, and biological pathways. Our recently launched Version 4 has a revamped infrastructure facilitating faster data updates, better-targeted data queries, and friendlier user experience. It also provides a stronger foundation for the GeneCards suite of companion databases and analysis tools. Improved data unification includes gene-disease links via MalaCards and merged biological pathways via PathCards, as well as drug information and proteome expression. VarElect, another suite member, is a phenotype prioritizer for next-generation sequencing, leveraging the GeneCards and MalaCards knowledgebase. It au- tomatically infers direct and indirect scored associations between hundreds or even thousands of variant-containing genes and disease phenotype terms. Var- Elect’s capabilities, either independently or within TGex, our comprehensive variant analysis pipeline, help prepare for the challenge of clinical projects that involve thousands of exome/genome NGS analyses.
    [Show full text]
  • Functional Specialization of Human Salivary Glands and Origins of Proteins Intrinsic to Human Saliva
    UCSF UC San Francisco Previously Published Works Title Functional Specialization of Human Salivary Glands and Origins of Proteins Intrinsic to Human Saliva. Permalink https://escholarship.org/uc/item/95h5g8mq Journal Cell reports, 33(7) ISSN 2211-1247 Authors Saitou, Marie Gaylord, Eliza A Xu, Erica et al. Publication Date 2020-11-01 DOI 10.1016/j.celrep.2020.108402 Peer reviewed eScholarship.org Powered by the California Digital Library University of California HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Cell Rep Manuscript Author . Author manuscript; Manuscript Author available in PMC 2020 November 30. Published in final edited form as: Cell Rep. 2020 November 17; 33(7): 108402. doi:10.1016/j.celrep.2020.108402. Functional Specialization of Human Salivary Glands and Origins of Proteins Intrinsic to Human Saliva Marie Saitou1,2,3, Eliza A. Gaylord4, Erica Xu1,7, Alison J. May4, Lubov Neznanova5, Sara Nathan4, Anissa Grawe4, Jolie Chang6, William Ryan6, Stefan Ruhl5,*, Sarah M. Knox4,*, Omer Gokcumen1,8,* 1Department of Biological Sciences, University at Buffalo, The State University of New York, Buffalo, NY, U.S.A 2Section of Genetic Medicine, Department of Medicine, University of Chicago, Chicago, IL, U.S.A 3Faculty of Biosciences, Norwegian University of Life Sciences, Ås, Viken, Norway 4Program in Craniofacial Biology, Department of Cell and Tissue Biology, School of Dentistry, University of California, San Francisco, CA, U.S.A 5Department of Oral Biology, School of Dental Medicine, University at Buffalo, The State University of New York, Buffalo, NY, U.S.A 6Department of Otolaryngology, School of Medicine, University of California, San Francisco, CA, U.S.A 7Present address: Weill-Cornell Medical College, Physiology and Biophysics Department 8Lead Contact SUMMARY Salivary proteins are essential for maintaining health in the oral cavity and proximal digestive tract, and they serve as potential diagnostic markers for monitoring human health and disease.
    [Show full text]
  • Human Induced Pluripotent Stem Cell–Derived Podocytes Mature Into Vascularized Glomeruli Upon Experimental Transplantation
    BASIC RESEARCH www.jasn.org Human Induced Pluripotent Stem Cell–Derived Podocytes Mature into Vascularized Glomeruli upon Experimental Transplantation † Sazia Sharmin,* Atsuhiro Taguchi,* Yusuke Kaku,* Yasuhiro Yoshimura,* Tomoko Ohmori,* ‡ † ‡ Tetsushi Sakuma, Masashi Mukoyama, Takashi Yamamoto, Hidetake Kurihara,§ and | Ryuichi Nishinakamura* *Department of Kidney Development, Institute of Molecular Embryology and Genetics, and †Department of Nephrology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan; ‡Department of Mathematical and Life Sciences, Graduate School of Science, Hiroshima University, Hiroshima, Japan; §Division of Anatomy, Juntendo University School of Medicine, Tokyo, Japan; and |Japan Science and Technology Agency, CREST, Kumamoto, Japan ABSTRACT Glomerular podocytes express proteins, such as nephrin, that constitute the slit diaphragm, thereby contributing to the filtration process in the kidney. Glomerular development has been analyzed mainly in mice, whereas analysis of human kidney development has been minimal because of limited access to embryonic kidneys. We previously reported the induction of three-dimensional primordial glomeruli from human induced pluripotent stem (iPS) cells. Here, using transcription activator–like effector nuclease-mediated homologous recombination, we generated human iPS cell lines that express green fluorescent protein (GFP) in the NPHS1 locus, which encodes nephrin, and we show that GFP expression facilitated accurate visualization of nephrin-positive podocyte formation in
    [Show full text]